中国组织工程研究

中国组织工程研究 ›› 2012, Vol. 16 ›› Issue (43): 8111-8116.doi: 10.3969/j.issn.2095-4344.2012.43.027

• 生物材料综述 biomaterial review • 上一篇    下一篇

精氨酸-甘氨酸-天冬氨酸肽类似物与新生血管内皮靶向治疗

周艳芳1, 2，邓宇斌2   

  1. 1广东医学院病理生理学教研室，广东省东莞市 523808
    2中山大学医学院病理生理学教研室，广东省广州市 510080
  • 收稿日期:2011-12-05 修回日期:2011-12-28 出版日期:2012-10-21 发布日期:2013-04-08
  • 通讯作者: 邓宇斌，博士，教授，中山大学医学院病理生理学教研室，广东省广州市 510080 dengyub@ mail.sysu.edu.cn
  • 作者简介:周艳芳☆，女，1977年生，湖北省仙桃市人，汉族，2011年中山大学毕业，博士，副教授，主要从事新型纳米材料联合干细胞移植治疗缺血性脑病研究。 Fangfang772003@163.com

Development of arginine-glycine-aspartic acid peptide analogues in endothelial targeted therapy of neovascularization

Zhou Yan-fang1, 2, Deng Yu-bin2   

  1. 1Department of Pathophysiology, Guangdong Medical College, Dongguan 523808, Guangdong Province, China
    2Department of Pathophysiology, Medical School of Sun Yat-sen University, Zhongshan 510080, Guangdong Province, China
  • Received:2011-12-05 Revised:2011-12-28 Online:2012-10-21 Published:2013-04-08
  • Contact: Deng Yu-bin, Doctor, Professor, Department of Pathophysiology, Medical School of Sun Yat-sen University, Zhongshan 510080, Guangdong Province, China dengyub@ mail.sysu.edu.cn
  • About author:Zhou Yan-fang☆, Doctor, Associate professor, Department of Pathophysiology, Guangdong Medical College, Dongguan 523808, Guangdong Province, China; Department of Pathophysiology, Medical School of Sun Yat-sen University, Zhongshan 510080, Guangdong Province, China Fangfang772003@ 163.com

PDF

710

被引次数

2

摘要：

背景：血管内皮是缺血、血栓、炎症、水肿、氧化应激等病理损伤中的重要部位，选择特异性的内皮细胞靶点成为药物介入治疗的关键。
目的：分析和总结近年来精氨酸-甘氨酸-天冬氨酸肽及精氨酸-甘氨酸-天冬氨酸多肽类似物作为特异性的内皮细胞靶点的研究。
方法：分别以“RGD、整合素、靶向治疗”,“RGD、integrin 、targeted therapy” 为检索词，应用计算机检索Pubmed 数据库1998年1月至2011年12月有关文章。纳入有关血管新生的文献。排除与研究目的无关和内容重复者。保留42篇文献做进一步分析。
结果与结论：整合素αvβ3是内皮细胞病理损伤及血管新生时的特异靶点，参与内皮细胞的迁移、增殖、分化过程。精氨酸-甘氨酸-天冬氨酸肽及精氨酸-甘氨酸-天冬氨酸多肽类似物作为整合素和其配体相互作用的识别位点，能结合肿瘤或者病理损伤时新生血管表达增高的整合素αvβ3，介导细胞与细胞外基质及细胞之间的相互作用，可在新生血管显影、靶向药物递送、载体材料修饰中发挥重要作用。

关键词: 精氨酸-甘氨酸-天冬氨酸肽, 新生血管, 整合素, 靶向治疗, 生物材料

Abstract:

BACKGROUND: Vascular endothelium plays an important role in ischemia, thrombosis, inflammation, edema, oxidative stress and other pathological damages. It is critical to select the specific endothelial target for drug intervention.
OBJECTIVE: To analyze and summarize the researches about arginine-glycine-aspartic acid (RGD) peptide and its analogues used as specific endothelial targets in recent years.
METHODS: A computer-based online search of related articles published from January 1998 to December 2011 was performed in PubMed database using the key words of “RGD, integrin, targeted therapy”. The documents related to neovascularization were included. The literatures of irrelevant purpose and repetitive content were excluded. Finally, 42 literatures were chosen to summarize.
RESULTS AND CONCLUSION: Integrin αvβ3 is the specific target in pathological damage of endothelial cells and neovascularization which is involved in the migration, proliferation and differentiation of endothelial cells. As the interacting recognition sites of integrin and its ligand, RGD peptide can be combined with integrin αvβ3 with high expression in tumor or pathological angiogenesis, and can mediate the interactions between cell-extracellular matrix and cell and cells. RGD peptide plays an important role in angiogenesis imaging, targeted drug delivery and carrier material modification.

中图分类号: